SI3551627T1 - Novi derivati izoksazolil etra kot GABA A ALFA5 PAM - Google Patents

Novi derivati izoksazolil etra kot GABA A ALFA5 PAM

Info

Publication number
SI3551627T1
SI3551627T1 SI201731124T SI201731124T SI3551627T1 SI 3551627 T1 SI3551627 T1 SI 3551627T1 SI 201731124 T SI201731124 T SI 201731124T SI 201731124 T SI201731124 T SI 201731124T SI 3551627 T1 SI3551627 T1 SI 3551627T1
Authority
SI
Slovenia
Prior art keywords
alpha5
gaba
pam
ether derivatives
new
Prior art date
Application number
SI201731124T
Other languages
English (en)
Inventor
Bernd Buettelmann
Giuseppe Cecere
Bernhard Fasching
Zbinden Katrin Groebke
Maria-Clemencia Hernandez
Henner Knust
Andreas Koblet
Emmanuel Pinard
Andrew Thomas
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3551627T1 publication Critical patent/SI3551627T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI201731124T 2016-12-08 2017-12-07 Novi derivati izoksazolil etra kot GABA A ALFA5 PAM SI3551627T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16202889 2016-12-08
PCT/EP2017/081768 WO2018104419A1 (en) 2016-12-08 2017-12-07 New isoxazolyl ether derivatives as gaba a alpha5 pam
EP17816630.2A EP3551627B1 (en) 2016-12-08 2017-12-07 New isoxazolyl ether derivatives as gaba a alpha5 pam

Publications (1)

Publication Number Publication Date
SI3551627T1 true SI3551627T1 (sl) 2022-05-31

Family

ID=57530563

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731124T SI3551627T1 (sl) 2016-12-08 2017-12-07 Novi derivati izoksazolil etra kot GABA A ALFA5 PAM

Country Status (30)

Country Link
US (2) US11091471B2 (sl)
EP (1) EP3551627B1 (sl)
JP (1) JP7084405B2 (sl)
KR (1) KR102564643B1 (sl)
CN (2) CN109923113B (sl)
AR (1) AR110498A1 (sl)
AU (1) AU2017373734B2 (sl)
BR (1) BR112019006571A2 (sl)
CA (1) CA3040024A1 (sl)
CL (1) CL2019001458A1 (sl)
CO (1) CO2019002692A2 (sl)
CR (1) CR20190268A (sl)
DK (1) DK3551627T3 (sl)
ES (1) ES2910110T3 (sl)
HR (1) HRP20220468T1 (sl)
HU (1) HUE058355T2 (sl)
IL (1) IL267054B (sl)
LT (1) LT3551627T (sl)
MA (1) MA48594B1 (sl)
MX (1) MX2019006696A (sl)
PE (1) PE20191156A1 (sl)
PH (1) PH12019500664A1 (sl)
PL (1) PL3551627T3 (sl)
PT (1) PT3551627T (sl)
RS (1) RS63106B1 (sl)
SI (1) SI3551627T1 (sl)
TW (1) TWI642666B (sl)
UA (1) UA125524C2 (sl)
WO (1) WO2018104419A1 (sl)
ZA (1) ZA201902225B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3551627T3 (pl) 2016-12-08 2022-05-16 F. Hoffmann-La Roche Ag Nowe pochodne eterowe izoksazolilu jako PAM dla GABA A alfa-5
MA52868A (fr) 2018-06-13 2021-04-21 Hoffmann La Roche Nouveaux dérivés d'isoxazolyle éther en tant que gaba a alpha5 pam
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
EP4126858A1 (en) * 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物
KR20240005848A (ko) 2021-05-05 2024-01-12 유니버시티 칼리지 카디프 컨설턴츠 리미티드 인지 장애의 치료에 유용한 헤테로아릴 화합물
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023247389A1 (en) 2022-06-20 2023-12-28 F. Hoffmann-La Roche Ag Crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4- yl)methoxy)-n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide
WO2024088928A1 (en) 2022-10-25 2024-05-02 F. Hoffmann-La Roche Ag Process for manufacturing alogabat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682301A1 (en) 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
RU2484091C2 (ru) * 2007-12-04 2013-06-10 Ф. Хоффманн-Ля Рош Аг Производные изоксазоло-пиридина
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
CA2760166C (en) 2009-05-05 2017-07-18 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
KR20130083927A (ko) 2010-11-05 2013-07-23 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 활성 약학 화합물의 용도
PE20141372A1 (es) * 2011-09-15 2014-10-13 Hoffmann La Roche Nuevos derivados dihidroquinolina-2-ona
US20200101068A1 (en) 2015-08-17 2020-04-02 Lupin Limited Heteroaryl Derivatives as PARP Inhibitors
CN108430473B (zh) 2016-01-08 2021-08-31 细胞基因公司 抗增殖化合物以及其药物组合物和用途
PT3399984T (pt) 2016-01-08 2023-11-21 Arcus Biosciences Inc Moduladores da 5' nucleotidase, ecto e sua utilização
PL3551627T3 (pl) 2016-12-08 2022-05-16 F. Hoffmann-La Roche Ag Nowe pochodne eterowe izoksazolilu jako PAM dla GABA A alfa-5

Also Published As

Publication number Publication date
CL2019001458A1 (es) 2019-10-18
ZA201902225B (en) 2019-12-18
RU2019118253A3 (sl) 2021-04-07
CN109923113B (zh) 2023-10-13
CN109923113A (zh) 2019-06-21
CR20190268A (es) 2019-07-11
CN117285525A (zh) 2023-12-26
US20190300516A1 (en) 2019-10-03
PL3551627T3 (pl) 2022-05-16
HRP20220468T1 (hr) 2022-05-27
RU2019118253A (ru) 2021-01-11
TW201827424A (zh) 2018-08-01
UA125524C2 (uk) 2022-04-13
US11091471B2 (en) 2021-08-17
PH12019500664A1 (en) 2019-12-16
TWI642666B (zh) 2018-12-01
WO2018104419A1 (en) 2018-06-14
DK3551627T3 (da) 2022-04-19
AR110498A1 (es) 2019-04-03
RS63106B1 (sr) 2022-04-29
BR112019006571A2 (pt) 2019-07-02
HUE058355T2 (hu) 2022-07-28
MA48594A (fr) 2021-04-28
PT3551627T (pt) 2022-04-06
AU2017373734A1 (en) 2019-04-11
MA48594B1 (fr) 2022-05-31
MX2019006696A (es) 2019-08-21
LT3551627T (lt) 2022-04-25
JP2020510621A (ja) 2020-04-09
EP3551627B1 (en) 2022-02-16
AU2017373734B2 (en) 2022-02-17
KR20190088485A (ko) 2019-07-26
US20220411415A1 (en) 2022-12-29
CO2019002692A2 (es) 2019-04-12
IL267054B (en) 2021-07-29
CA3040024A1 (en) 2018-06-14
KR102564643B1 (ko) 2023-08-08
PE20191156A1 (es) 2019-09-09
JP7084405B2 (ja) 2022-06-14
EP3551627A1 (en) 2019-10-16
IL267054A (en) 2019-08-29
ES2910110T3 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
IL267054B (en) New derivatives of isoxazolyl ether as gaba a alpha5 pam
GB201406235D0 (en) A table arrangement
GB201406238D0 (en) A table arrangement
GB201419951D0 (en) A guide vane
EP3159544C0 (en) SPIRAL FLUID MACHINE
PL3221372T3 (pl) Modyfikator reologii
GB201408170D0 (en) A clamp mechanism
IL279266A (en) New Isoxazolyl Ether History as GABA A ALPHA5 PAM
GB201513082D0 (en) A water turbine
PL3087867T3 (pl) Część wysuwana elementu szafy
HK1245102A1 (zh) 灌腸劑
HK1194910A2 (en) A ring
GB201408986D0 (en) A casing arrangement
PL3368779T3 (pl) Wkręt umożliwiający łatwe rozpoczynanie wkręcania
GB2525305B (en) A turbine
SG11201700014XA (en) A gasifier
GB2522489B (en) A collapsible airer for clothes
GB201417632D0 (en) Tap
TWI561320B (en) Tube expander
GB201618284D0 (en) A pipe
ZA201508308B (en) A push tap
GB2536412B (en) A casing
GB201400206D0 (en) A tap
AU5526P (en) Lompet1 Lomandra longifolia
GB201503624D0 (en) Pipe arrangement